All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

The Billion Dollar Question in Ovarian Cancer: What Therapies to Use for Maintenance and Recurrence

March 7th 2024

PARP inhibitors have shown promise in ovarian cancer treatment, but certain subgroups of patients have few effective options following disease progression.

Adjuvant Chemotherapy After Nephroureterectomy Offers DFS Benefit in Upper Tract Urothelial Cancer

March 7th 2024

Patients with upper tract urothelial cancer who received adjuvant chemotherapy after nephroureterectomy experienced extended DFS vs those who received surveillance.

FDA Approves Inotuzumab Ozogamicin for Pediatric CD22+ B-Cell Precursor Acute Lymphoblastic Leukemia

March 6th 2024

The FDA has approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Community-Based Clinical Trial Enrollment Expands Access to Prostate Cancer Care

March 6th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss enrollment to the ECLIPSE trial in community and academic cancer center settings.

Modesitt Reflects on the Art of Treatment Selection Amidst Expansion of Targeted and Immunotherapies in Gynecologic Oncology

March 6th 2024

The Center to Eliminate Cancer Inequity to address unequal burden of cancer driven by health disparities

March 6th 2024

A new center at the University of Chicago Medicine will tackle health inequities in cancer.

FDA Awards Orphan Drug Designation to Avutometinib Alone or With Defactinib for Recurrent Low-Grade Serous Ovarian Cancer

March 6th 2024

Avutometinib alone or in combination with defactinib has received an orphan drug from the FDA for recurrent low-grade serous ovarian cancer.

EMA Receives Indication Extension Application for D-VRd in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

March 6th 2024

The EMA has received a type II variation application for an indication extension of D-VRd for the treatment newly diagnosed multiple myeloma.

T-DXd Fails to Receive Recommendation From NICE for HER2-Low Breast Cancer Treatment

March 6th 2024

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Clinicians Report Unmet Needs Regarding Training Fellows for Community-Based Careers

March 6th 2024

Clinicians say that there are substantial unmet needs in terms of deliberately training hematology/oncology fellows for community-based careers.

Randall Details Inaugural Birmingham Orthopedic Oncology Meeting

March 6th 2024

R. Lor Randall, MD, FACS, discusses the top takeaways from the inaugural 2024 Birmingham Orthopedic Oncology Meeting.

Endoscopy and ctDNA Assays May Help Facilitate, Optimize Nonoperative Management of Select GI Cancers

March 5th 2024

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA assays to guide nonoperative approaches in select gastrointestinal cancers.

Iopofosine Plus EBRT Produces Remissions, Proves Safe in Recurrent/Metastatic Head and Neck Cancer

March 5th 2024

Iopofosine plus EBRT elicited a 64% CR rate and was well tolerated in patients with locoregionally recurrent/metastatic head and neck cancer.

FDA Approves 2 Denosumab Biosimilars for All Reference Medicine Indications

March 5th 2024

The FDA has approved the biosimilars denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti) for use in all indications of the reference medicines denosumab (Xgeva) and denosumab (Prolia).

Frontline Lenvatinib Plus Pembrolizumab Generates Responses But Fails to Produce OS Benefit in HNSCC

March 5th 2024

Adding lenvatinib to pembrolizumab improved ORR and PFS, but not OS, vs placebo for patients with head and neck squamous cell carcinoma.

Kidney Cancer Treatments and Tumor Biology Can Activate Different Immune-Modifying Processes in Patients

March 5th 2024

Different immunomodulatory mechanisms are at work depending on the type of treatment and the genetic makeup of the cancer in RCC.

Taletrectinib Under NMPA Review in China for First-Line ROS1+ NSCLC

March 5th 2024

China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.

NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer

March 5th 2024

The National Institute for Health and Care Excellence recommends the approval of dostarlimab plus chemotherapy for advanced/recurrent endometrial cancer.

2024 Outlook on Cancer Care: Striving to Overcome the Challenges

March 5th 2024

Although novel therapies have improved cancer care, cancer diagnoses have increased, with more than 2 million new cases estimated for 2024.

Porter Discusses FDA’s Call for Secondary Malignancies Boxed Warning on CAR T-Cell Therapies

March 5th 2024

David L. Porter, MD, discusses the decision by the FDA to call for a boxed warning for secondary malignancies on all approved CAR T-cell agents.